Renin inhibition with aliskiren: where are we now, and where are we going?

Journal of Hypertension
Michel AziziN K Hollenberg

Abstract

With the development of aliskiren, blockade of the renin-angiotensin-aldosterone system (RAAS) at the level of the interaction of renin with a substrate has become a clinical reality. This review covers the specific features of the first agent likely to achieve widespread clinical exposure, aliskiren. The potential of renin inhibition must be viewed in the context of the remarkable efficacy of both angiotensin-converting enzyme (ACE) inhibition and angiotensin receptor blockers (ARBs). The implications of blockade of the renin system at its rate-limiting step are reviewed, with the therapeutic implications for both the renin inhibitor employed alone or the renin inhibitor combined with an ACE inhibitor or ARB. The relevant and necessary studies are ongoing.

References

Jan 1, 1976·Annual Review of Biochemistry·R L Soffer
Feb 1, 1992·Journal of Cardiovascular Pharmacology·M A FitzpatrickJ Nussberger
Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·D GantenU Ganten
May 1, 1990·Plastic and Reconstructive Surgery·J M PenslerJ B Mulliken
Sep 1, 1985·Hypertension·J M WoodK G Hofbauer
Jul 1, 1983·The Biochemical Journal·H Maruta, K Arakawa
May 1, 1993·American Journal of Hypertension·I KobrinV Charlon
May 1, 1996·American Heart Journal·C Lin, W H Frishman
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
May 16, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P van PaassenP E de Jong
Feb 28, 2001·Expert Opinion on Investigational Drugs·N D Fisher, N K Hollenberg
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Aug 21, 2003·Biochemical and Biophysical Research Communications·Jeanette M WoodMartin P Bedigian
Sep 1, 1957·The Journal of Experimental Medicine·L T SKEGGSN P SHUMWAY

❮ Previous
Next ❯

Citations

Mar 28, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Michel Azizi
Feb 25, 2010·European Journal of Clinical Pharmacology·Tuija TapaninenMikko Niemi
Mar 16, 2012·European Journal of Clinical Pharmacology·Laurent B NicolasJasper Dingemanse
Jul 25, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Agnes B Fogo
Sep 28, 2007·Cardiovascular Drugs and Therapy·Fábio P Taniguchi
Mar 7, 2012·Cardiovascular Drugs and Therapy·Michel Azizi, Joël Ménard
Aug 16, 2008·International Urology and Nephrology·Kostas C Siamopoulos, Rigas G Kalaitzidis
Mar 20, 2009·International Urology and Nephrology·Yasmin PashaDavid Goldsmith
Apr 20, 2007·Current Hypertension Reports·Yufeng HuangNancy A Noble
Jan 8, 2008·Current Hypertension Reports·Roland E Schmieder
Dec 3, 2010·Current Hypertension Reports·Genevieve Nguyen
May 18, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masanori AbeMasayoshi Soma
Aug 18, 2006·Current Opinion in Nephrology and Hypertension·Michel Azizi
Aug 19, 2007·Cardiology in Review·Reza SepehrdadDomenic A Sica
Dec 20, 2007·Cardiology in Review·Sum Lam, Mary Choy
Feb 3, 2011·Cardiology in Review·Howard S WeintraubArthur Schwartzbard
May 19, 2010·American Journal of Therapeutics·Zafar H IsrailiValmore Bermúdez
Jul 9, 2009·Current Opinion in Nephrology and Hypertension·Aldo J Peixoto, Marcelo Orias
Mar 1, 2008·Clinical and Experimental Pharmacology & Physiology·Grégoire Wuerzner, Michel Azizi
Mar 1, 2012·Nephrology·Chia-Ter Chao, Vin-Cent Wu
May 10, 2007·Heart·Morris J Brown
Feb 16, 2008·The Journal of Clinical Investigation·Hong LuAlan Daugherty
Apr 23, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Motoharu TanakaHiromi Goto
Jan 11, 2007·Bioscience, Biotechnology, and Biochemistry·Tsutomu NakagawaYukio Nakamura
Oct 20, 2006·Clinical Pharmacokinetics·Charlie ZhaoHans Armin Dieterich
Jul 10, 2008·Clinical Pharmacokinetics·Sujata VaidyanathanWilliam P Dole
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vivencio Barrios, Carlos Escobar
Sep 29, 2011·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeClaudio Borghi
Apr 19, 2011·World Journal of Cardiology·Gaurav Alreja, Jacob Joseph
Aug 24, 2013·BioMed Research International·Yoseph GebruYan Zhang
Dec 18, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Shahid Nadeem, Donald L Batisky
Jul 10, 2014·Naunyn-Schmiedeberg's Archives of Pharmacology·Erol AkpinarBeyzagul Polat
Nov 15, 2007·Current Cardiology Reports·Anton H van den Meiracker, A H Jan Danser
Mar 11, 2008·Expert Review of Cardiovascular Therapy·Steven G Chrysant
Mar 20, 2009·Expert Review of Cardiovascular Therapy·Hae-Young Lee, Byung-Hee Oh
Dec 25, 2009·Expert Review of Cardiovascular Therapy·Steven A Yarows
Sep 18, 2007·Expert Review of Cardiovascular Therapy·Y UresinZ G Ozunal
Aug 16, 2006·Expert Opinion on Drug Safety·Huifang Cheng, Raymond C Harris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.